🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Role of Postoperative Radiotherapy in T1-T2N0M0 Glottic Carcinoma Involving the Anterior Commissure

RecruitingNAAges 18 Years - anyAllSecond Affiliated Hospital, Zhejiang University, …
NCT07781085 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

There remains no uniform treatment modality for glottic laryngeal carcinoma. Current clinical guidelines broadly recommend surgery or radiotherapy as single modality treatment for early stage glottic laryngeal carcinoma. Glottic carcinoma with anterior commissure invasion is linked to inferior local control; both definitive radiotherapy alone or transoral laser microsurgery (TLM) may confer a higher risk of local recurrence compared with other glottic carcinomas. We hypothesize that postoperative radiotherapy can act as an effective adjunct to surgery and reduce recurrence rates in patients with glottic carcinoma involving the anterior commissure. This study aims to conduct a multicenter, prospective, single arm phase II clinical trial of intensity modulated radiotherapy (IMRT) for postoperative patients with early stage glottic laryngeal carcinoma and anterior commissure involvement, to

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Aged 18 years or older, regardless of gender; 2. Pathologically confirmed glottic squamous cell carcinoma; 3. T1-T2N0M0 glottic laryngeal carcinoma with anterior commissure involvement; 4. Patients who have undergone curative intent surgery for glottic carcinoma with negative surgical margins, within 4-8 weeks post operation; 5. No prior radiotherapy, chemotherapy or other anti neoplastic agent treatment; 6. ECOG performance status of 0 or 1; 7. Signed informed consent form. Exclusion Criteria: 1. Patients without anterior commissure involvement; 2. Prior chemotherapy or treatment with other anti neoplastic agents; 3. Prior history of head and neck radiotherapy; 4. Prior participation in other clinical trials; 5. Patients with severe allergy history or allergic diathesis, e.g., contrast medium allergy; 6. Pregnant or lactating women; 7. Patients with uncontrolled acute infection; 8. Patients with drug addiction, substance abuse, chronic heavy alcohol consumption, or human immunodeficiency virus (HIV) infection; 9. Patients with other uncontrolled concurrent malignancies.
💊

What it tests

  • intensity modulated radiotherapy (IMRT)
📍

Where

1 site
Second Affiliated Hospital Of Zhejiang University School of Medicine
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy